Efficacy, Durability, And Retreatment Outcomes Of Risankizumab In Moderate To Severe Plaque Psoriasis: Results From The Phase 3 Immhance Trial. JOC [Internet]. 2016 Dec. 25 [cited 2026 Mar. 17];15(1). Available from: https://carcinogenesis.com/index.php/JOC/article/view/1825